Poor English can delay the publication of research. A latest article in New Scientist, a British weekly science magazine, mentions that poor English “is another factor that puts some scientists at a disadvantage. Rudolf Jaenisch at the Massachusetts Institute of Technology, the leading US-based researcher working on iPS cells, argues that some papers from Asia are so […]
Heart failure or the heart muscle’s inability to pump blood efficiently affects approximately 37 million people worldwide. Almost half of the patients diagnosed with heart failure die within five years of the diagnosis. While there is slew of research on heart failure and its treatments, a promising fresh examine may contribute significantly to heart muscle function.
In the trial, 30 patients inbetween the ages of Eighteen to 75 diagnosed with stable heart failure received intravenous infusions of umbilical cord-derived stem cells. Stem cell infusion was also derived from the umbilical straps intravenously. The results suggest that the IV-infused umbilical cord-derived from stem cells helps improve the heart’s capability to pump blood without any adverse effects. The fresh heart failure treatment displayed sustained improvement of the heart muscle function and quality of life. The study’s corresponding author Fernando Figueroa, M.D., professor of medicine at the Universidad de los Andes in Chile said, “We are encouraged by our findings because they could pave the way to a non-invasive, promising fresh therapy for a group of patients who face grim odds.”
There has been slew of research on the potential of bone marrow-derived stem cells as treatment. Albeit umbilical cord-derived stem cells have never been evaluated, they provide greater potential because of the effortless accessibility and availability. While larger studies will have to be conducted to assess the scope of potential benefits and risks, if any, these findings provide a promising option for heart failure treatment.
Jorge Bartolucci M.D.
Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/Two Randomized Managed Trial (RIMECARD Trial).
Circulation Research, DOI: Ten.1161/CIRCRESAHA.117.310712